* S&P - Danaher Corp. 'A' ratings placed on watch negative on planned acqusition of Cepheid
Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.
Sept 6 Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.
* Moody's: Danaher's A2 rating unaffected by planned acquisition of Cepheid for $4 billion Source text for Eikon: Further company coverage:,
* Danaher to acquire Cepheid for $53.00 per share, or approximately $4 billion
Sept 6 Danaher Corp said it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt.
* Q1 earnings per share view $0.01 -- Thomson Reuters I/B/E/S
* Cepheid announces partner distribution agreement with medline
|Roche Holding Ltd. (ROG.S)||CHF243.50||+1.40|
|Roche Holding Ltd. (RO.S)||CHF244.10||+1.40|
|Abbott Laboratories (ABT.N)||$42.33||+0.65|
|Becton Dickinson and Co (BDX.N)||$178.97||+1.96|
|Hologic, Inc. (HOLX.OQ)||$38.76||+0.79|
|BioMerieux SA (BIOX.PA)||€136.00||+0.10|
|Qiagen NV (QGEN.OQ)||$27.12||+0.60|
|Luminex Corporation (LMNX.OQ)||$22.73||+0.17|
|Meridian Bioscience, Inc. (VIVO.OQ)||$19.68||+0.10|
|Quidel Corporation (QDEL.OQ)||$22.11||-0.06|
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Trading Report for (CPHD). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.